Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21 FDA approval of Investigational New Drug (IND) application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results